Current Psychopharmacology最新文献_第6页

Psychopharmacology for Patients with Parkinson’s Disease and Deep Brain Stimulation: Lessons Learned in an Academic Center 帕金森氏病患者的精神药理学和脑深部刺激:一个学术中心的经验教训

Current Psychopharmacology Pub Date : 2019-03-31 DOI: 10.2174/2211556007666180328142953

A. Seritan, Peter J Ureste, Tammy Duong, J. Ostrem

{"title":"Psychopharmacology for Patients with Parkinson’s Disease and Deep Brain Stimulation: Lessons Learned in an Academic Center","authors":"A. Seritan, Peter J Ureste, Tammy Duong, J. Ostrem","doi":"10.2174/2211556007666180328142953","DOIUrl":"https://doi.org/10.2174/2211556007666180328142953","url":null,"abstract":"Deep brain stimulation (DBS) is a modern neuromodulation method used in the treatment of advanced movement disorders such as Parkinson’s disease (PD) and dystonia. Patients with PD may have multiple psychiatric comorbidities, notably anxiety, depression, mania or hypomania, and psychosis. DBS surgery may indirectly alleviate psychiatric symptoms by allowing reduction of dopaminergic medications, or as a result of functional improvement. Patients who are considering DBS for PD often have more advanced disease and may be more vulnerable to perioperative psychiatric decline. Albeit infrequently, increased depression, apathy, irritability, hypomania or mania, and suicidal behavior have been observed after DBS surgery. Objective: This review aimed to present current evidence and empirical recommendations for the management of the psychiatric symptoms in patients with PD treated with DBS. Method: Relevant literature was reviewed and synthesized, along with recommendations informed by the authors’ clinical experience in a large, academic DBS center.Careful evaluation of DBS candidacy, including assessing the risk for perioperative psychiatric decompensation is advised. Maintaining at least eight weeks of psychiatric stability prior to DBS surgery is strongly recommended. Postoperative management can be challenging due to advanced disease, concurrent psychiatric comorbidities, and possible DBS stimulation-related effects on mood and impulse control. Stimulation-induced elevated mood states (mania, hypomania) have started to be recognized as distinct clinical entities, although not included in the current psychiatric nomenclature.Insufficient evidence-based strategies for managing psychiatric symptoms in PD patients with DBS exist at this time. Further research is necessary to uncover best practices in this complex, expanding field.","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89084888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Meet Our Editorial Board Member 见见我们的编辑委员会成员

Current Psychopharmacology Pub Date : 2019-03-18 DOI: 10.2174/221155600801190318123258

C. Stevenson

引用次数: 1

Protein Chimera-based Ca2+ Rewiring as a Treatment Modality for Neurodegeneration 基于蛋白嵌合体的Ca2+重新布线作为神经退行性疾病的治疗方式

Current Psychopharmacology Pub Date : 2019-03-18 DOI: 10.2174/2211556007666181001102702

N. U. Rajesh, Anam Qudrat

引用次数: 0

Systemic Injections of Primidone Cause Wake-Inducing Effects in Rats 全身注射普里米酮引起大鼠清醒诱导作用

Current Psychopharmacology Pub Date : 2019-03-18 DOI: 10.2174/2211556007666180425143506

Mireille Salas-Crisóstomo, María José Franco-Tormo, Niurka Trujillo-Paredes, G. Arankowsky-Sandoval, Ó. Arias-Carrión, S. Machado, E. Murillo-Rodríguez

{"title":"Systemic Injections of Primidone Cause Wake-Inducing Effects in Rats","authors":"Mireille Salas-Crisóstomo, María José Franco-Tormo, Niurka Trujillo-Paredes, G. Arankowsky-Sandoval, Ó. Arias-Carrión, S. Machado, E. Murillo-Rodríguez","doi":"10.2174/2211556007666180425143506","DOIUrl":"https://doi.org/10.2174/2211556007666180425143506","url":null,"abstract":"\u0000\u0000 Essential Tremor (ET) is a disease present in neurodegenerative disorders,\u0000such as Parkinson´s disease. Besides the motor dysfunction, ET also causes sleep problems, including\u0000excessive daytime sleepiness. To manage ET, several compounds are prescripted, such as\u0000primidone. However, no evidence is available regarding the effects of primidone on sleep.\u0000\u0000Objective: We analyzed the effects of systemic injections of primidone on sleep in rats.\u0000\u0000Method: Rats with sleep electrodes received different doses of primidone (0, 5, 10 or\u000050mg/Kg, i.p.) at the beginning of the lights-on period. Next, the effects of primidone on the\u0000states of vigilance were characterized.\u0000\u0000\u0000\u0000 At the highest dose of primidone (50mg/Kg), animals displayed an increase in Wakefulness\u0000(W) whereas Slow Wave Sleep (SWS) and Rapid Eye Movement Sleep (REMS) were decreased.\u0000In addition, sleep parameters such as the number of bouts, mean duration and latency\u0000were affected in primidone-treated animals. In this regard, the drug caused an enhancement in the\u0000number of bouts of W and SWS while the number of events of REMS showed a diminution. Regarding\u0000the mean duration, we found that SWS was decreased after primidone treatments whereas\u0000W and REMS remained with no statistical changes. Lastly, the latency of SWS was enhanced\u0000in primidone-treated animals while no statistical changes were found in REMS.\u0000\u0000\u0000\u0000 Our findings demonstrate that primidone, a drug that is used to control ET, provokes\u0000wake-inducing effects in rats.","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73215079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Neurobehavioral Effects of β-Escin β-叶esin的神经行为效应

Current Psychopharmacology Pub Date : 2019-03-18 DOI: 10.2174/2211556007666180523103828

H. Waheed, S. B. Nashtar, Ali I. Al-Gareeb, H. Al-kuraishy

{"title":"Neurobehavioral Effects of β-Escin","authors":"H. Waheed, S. B. Nashtar, Ali I. Al-Gareeb, H. Al-kuraishy","doi":"10.2174/2211556007666180523103828","DOIUrl":"https://doi.org/10.2174/2211556007666180523103828","url":null,"abstract":"\u0000\u0000 Aescin or β-escin is the main and active constituent of horse chestnut\u0000seed (Aesculus hippocastanum) used for the treatment of inflammatory edema, venous insufficiency\u0000and ischemic ulcerations. Aescin has many actions due to induction of endothelial\u0000nitric oxide and prostaglandin F2-α production moreover; aescin antagonizes the effect of histamine\u0000and 5HT at receptor levels.\u0000\u0000Objective: The aim of the present study was to evaluate the neurobehavioral effects of aescin\u0000on normal healthy volunteers.\u0000\u0000Method: A total number of 65 healthy participants with mean age of 21+1.1 years were recruited\u0000to study the effects of aescin on the neurobehavioral effects of normal healthy volunteers\u0000compared to placebo. The neurobehavioral effects were assessed by psychomotor performances\u0000and sensorimotor reaction, cortical arousal and central integrity processes and assessment\u0000of memory capacity.\u0000\u0000\u0000\u0000 Placebo produced insignificant amelioration of TRT and RRT p>0.05, with mild\u0000significant effect on MRT p=0.03. Aescin produced a significant effect in the amelioration of\u0000psychomotor performances and sensorimotor reaction p=0.0001. Regarding the differential\u0000effect of placebo and aescin on the cortical arousal and central integrity processes, placebo illustrated\u0000insignificant effect at p>0.05 whereas; aescin showed mild significant effect on Critical\u0000Fusion Frequency (CFFA) p<0.05 and highly significant effect on the other parameters\u0000p<0.01 except for critical-fusion frequency threshold when aescin illustrated insignificant effect\u0000at p>0.05. Aescin illustrated significant acceleration of ІІ-back WMA, ІІІ-back WMA\u0000and Second trial Short-Term Memory (STM) at p<0.01 compared to the placebo effect.\u0000\u0000\u0000\u0000 Short-term therapy with aescin improves the neurobehavioral effects on healthy\u0000volunteers.","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"84 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89032393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Comparative Evaluation of A Partial Dopamine Agonist with A Preferential D2 and D3 Receptor Antagonist on Ethanol Induced Conditioned Place Preference in Mice 部分多巴胺激动剂与优先D2和D3受体拮抗剂对乙醇诱导小鼠条件位置偏好的比较评价

Current Psychopharmacology Pub Date : 2019-03-18 DOI: 10.2174/2211556007666180705130103

M. A. Yazdani, M. J. Anwar, B. Parveen, D. Vohora

{"title":"Comparative Evaluation of A Partial Dopamine Agonist with A Preferential D2 and D3 Receptor Antagonist on Ethanol Induced Conditioned Place Preference in Mice","authors":"M. A. Yazdani, M. J. Anwar, B. Parveen, D. Vohora","doi":"10.2174/2211556007666180705130103","DOIUrl":"https://doi.org/10.2174/2211556007666180705130103","url":null,"abstract":"\u0000\u0000 The role of dopamine receptor sub-families in the rewarding and reinforcing\u0000effects of drugs of abuse has been established in numerous studies.\u0000\u0000Objectives: In view of the extensive role of mesolimbic dopaminergic transmission in rewarding\u0000and reinforcing effect of abused drugs including ethanol, the present study evaluated\u0000three mechanistically different drugs viz a partial dopaminergic agonist (PDA, aripiprazole),\u0000preferential D3 (mixed D2/D3) receptor antagonist (nafadotride), and a preferential D2 antagonist\u0000(haloperidol), on ethanol-induced conditioned place preference (CPP) in mice.\u0000\u0000Method: The study was carried out in Swiss strain albino mice. Ethanol (20%, 2g/kg) was\u0000used to induce CPP in mice. After the acquisition of CPP, behavioral tests (elevated plus\u0000maze and locomotor activity) were conducted and effect of drugs on expression and on reinstatement\u0000(after extinction) was studied.\u0000\u0000\u0000\u0000 We found that aripiprazole (1 and 2 mg/kg but not 0.5mg/kg), haloperidol (0.2\u0000mg/kg), and nafadotride (4.5 mg/kg) administered for 1 week during the conditioning phase\u0000prevented acquisition, expression and reinstatement of ethanol-induced CPP. All the three\u0000drugs reduced the ethanol-induced locomotor stimulation and produced antianxiety effects in\u0000elevated plus maze following the acquisition of ethanol CPP.\u0000\u0000\u0000\u0000 Partial dopaminergic agonism by aripiprazole was found to be a better strategy\u0000for normalizing dopaminergic neurotransmission in alcoholics as seen in rodents.","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"85 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75821035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Calcium Channel Blocker Ameliorates Nicotine Withdrawal Symptoms in Mice 钙通道阻滞剂改善小鼠尼古丁戒断症状

Current Psychopharmacology Pub Date : 2019-01-23 DOI: 10.2174/2211556007666180403114258

Shikha Aggarwal, N. Bansal

引用次数: 2

Dietary Interventions for Diabetic Neuropathy & Nephropathy: A Review 糖尿病性神经病变和肾病的饮食干预:综述

Current Psychopharmacology Pub Date : 2019-01-23 DOI: 10.2174/2211556007666180420142729

Onkar Bedi, G. Kaur, Harjeet Singh, P. Krishan

引用次数: 0

Anticholinergic and Hypocholesterolemic Activity of Juglan regia Improves Cognitive Functions in Mice 核桃的抗胆碱能和降胆固醇活性改善小鼠认知功能

Current Psychopharmacology Pub Date : 2019-01-23 DOI: 10.2174/2211556007666180629144844

Deepa Khanna and Milind Parle

引用次数: 0

Herbal Medication and Nutraceuticals for the Management of Anxiety and Depression 治疗焦虑和抑郁的草药和营养品

Current Psychopharmacology Pub Date : 2019-01-23 DOI: 10.2174/2211556007666180706155506

Sara Nidal Abed, Fatimah Amin Younes, H. Surchi, P. Deb

引用次数: 1